Genmab | GEN - Equity Capital And Reserves


Genmab reported DKK5.85B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.19B 91.22M Dec/2025
Almirall EUR 1.49B 24.03M Dec/2025
Amarin USD 459.28M 387K Dec/2025
Amgen USD 8.66B 961M Dec/2025
argenx SE USD 6.1B 597.47M Jun/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Bayer EUR 25.95B 3.75B Dec/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Demant DKK 9.84B 446M Dec/2025
Exelixis USD 2.16B 619K Dec/2025
Fresenius Medical Care EUR 249.82M 12.7B Dec/2025
Galapagos EUR 3.24B 788.91M Dec/2025
Genmab DKK 5.85B 96M Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
GN Store Nord DKK 14.88B 4.33B Dec/2025
GRIFOLS EUR 5.29B 108.05M Dec/2025
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 28.59B 344M Dec/2025
Novartis USD 46.13B 1.38B Dec/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 71.71B 1.55B Dec/2025
UCB EUR 10.87B 1.18B Dec/2025